Allergychoices
Allergychoices is a Wisconsin-based, privately held healthcare services company that commercializes the La Crosse Method Protocol for personalized sublingual immunotherapy, operating a licensed pharmacy, training a U.S. provider network, and serving individual allergy patients and employer health plans.
- Company typePrivate
- Founded2000
- HeadquartersOnalaska, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Allergychoices does
Allergychoices is a privately held U.S. healthcare services company founded in 2000 by Dr. David Morris and headquartered in Onalaska, Wisconsin. The company commercializes the La Crosse Method Protocol, a published sublingual immunotherapy (SLIT) framework that has been in clinical use since the late 1960s, treating environmental, food, and related allergic conditions through personalized liquid antigen drops rather than conventional allergy shots. Allergychoices operates a licensed pharmacy that formulates patient-specific 90-day prescriptions from FDA-approved antigen extracts in a glycerin base, and it trains a network of 2,000+ U.S. providers (allergists, ENTs, DPC clinicians) who prescribe the drops to their patients.
The company's product surface spans allergy drops, the La Crosse Method Protocol itself, allergy diagnostics, provider training and clinical support, and digital patient/provider portals. It also markets the Allergy Control Program, a turnkey B2B offering for self-insured employers, onsite/near-site clinics, DPC networks, and benefits consultants that bundles diagnostics, training, and treatment delivery into employer health plans, including nationwide telehealth. Across its history the company reports having treated 275,000+ patients with documented safety outcomes (97% adherence, 92% pharmacy satisfaction, 95% convenience ratings, no life-threatening reactions across 1B+ doses).
Allergychoices generates revenue primarily through recurring 90-day prescription sales priced at less than $150 for environmental allergies and less than $175 for food allergies, typically paid out-of-pocket since most insurers do not cover SLIT. Secondary revenue comes from provider training and clinical support services and from employer-facing Allergy Control Program contracts. The company is bootstrapped (no disclosed funding rounds), operates exclusively in the United States, and runs with a small headcount of 11-50 employees.
Allergychoices firmographics
Firmographics- Name
- Allergychoices
- Legal name
- Allergychoices
- Website
- https://allergychoices.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Allergychoices is a Wisconsin-based, privately held healthcare services company that commercializes the La Crosse Method Protocol for personalized sublingual immunotherapy, operating a licensed pharmacy, training a U.S. provider network, and serving individual allergy patients and employer health plans.
- Ownership category
- akta.pro rank
Allergychoices industry classification
Industry- Product category
- Allergy Treatment Services
- NAICS
- Offices of Physicians (62111), Pharmacies and Drug Retailers (456110)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF)
- akta.pro secondary industries
- Allergy & Immunology Clinics (HLAKAAAA), Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI), Food Allergy Evaluation & Management (HLAKAAAD), Pediatric Allergy & Immunology (HLAKAAAB), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where Allergychoices is headquartered
LocationHeadquarters
- HQ city
- Onalaska
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Allergychoices business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Prescription Allergy Drop Sales: Allergychoices operates a licensed pharmacy that formulates and dispenses patient-tailored allergy drop prescriptions. Prescriptions are sold directly to patients (typically through provider prescriptions) with recurring revenue from 90-day prescription refills. Treatment typically lasts 3-5 years, creating long-term customer relationships.
- Provider Training and Support Services: Provides training to healthcare providers on implementing the La Crosse Method Protocol, ongoing clinical support, and diagnostic tools. Supports the provider network that prescribes allergy drops.
- Allergy Control Program (Employer): Turnkey program for employers that includes diagnostic tools, provider training, and workflow integration. Works with onsite/near-site clinics, DPC networks, and contracted provider groups to deliver allergy treatment as part of employer health benefits.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Environmental Allergies - 90-day prescription |
| Subscription | Multi-year contract | Food Allergies - 90-day prescription |
| Subscription | Multi-year contract | Custom multi-antigen treatment |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels8 records
Allergychoices product offering
Product offeringCore offering
Allergychoices is a healthcare services and pharmacy company that formulates and dispenses personalized sublingual immunotherapy (allergy drops) under the proprietary La Crosse Method Protocol. Its licensed pharmacy takes FDA-approved antigen extracts and produces custom 90-day prescriptions tailored to each patient's allergic fingerprint, while the company also trains and supports a network of 2,000+ allergists, ENTs, and Direct Primary Care providers, and delivers an Allergy Control Program turnkey offering for employer health plans.
Product overview
Allergychoices is a healthcare services company offering sublingual immunotherapy (allergy drops) treatment for allergic diseases. The core offering consists of the La Crosse Method Protocol, a published treatment approach developed in 1970 that guides personalized allergy drop therapy. Services include a licensed pharmacy for custom prescription formulation, provider training programs, allergy diagnostics, and digital portals for patients and providers. The company also operates an Allergy Control Program for employers to provide workplace allergy treatment solutions. The treatment uses FDA-approved antigen extracts in a glycerin base, customized to each patient's specific allergies and sensitivity levels determined through testing.
Differentiator
Problem solved
Functional benefit
Products and services
- Allergy Drops (Sublingual Immunotherapy) Customized liquid allergy drops administered under the tongue following the La Crosse Method Protocol; treats the root cause of allergic disease by gradually building tolerance to identified allergens. Sold to individual patients through prescriptions dispensed by the Allergychoices licensed pharmacy.
- Allergy Control Program Employer-facing turnkey program that provides diagnostic tools, provider training, and workflow integration to deliver allergy treatment as part of employer-sponsored health benefits. Targets self-insured employers seeking to reduce healthcare costs and improve workforce productivity.
- Provider Training & Education Training programs and ongoing clinical support for healthcare providers (allergists, ENTs, DPC providers) implementing the La Crosse Method Protocol in their practices, including sublingual immunotherapy training and certification.
- Allergy Diagnostics Diagnostic tools including skin testing and reference lab services to identify specific allergens and allergy severity levels, used to inform personalized sublingual immunotherapy prescriptions.
Quantifiable outcome
- 97% patient adherence rate reported
- +4 more outcomes
Companies that use Allergychoices
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles3 records
Allergychoices technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Allergychoices partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NeoPath HealthcoreNeoPath Health implements the Allergy Control Program for employer groups. Their clinical teams use Allergychoices' testing methods and treatment protocols, with Allergychoices providing clinical support. Positive patient feedback reported on the alternative allergy treatment option.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Allergychoices competitors and assessment
Company assessmentEmerging players
- Alladapt Immunotherapeutics: Clinical-stage company developing multi-food oral immunotherapy. Comparable to Allergychoices' multi-antigen food allergy thesis, addressing the same polysensitized patient population with an emerging platform approach.
- DBV Technologies: Developer of the Viaskin epicutaneous immunotherapy patch for food and environmental allergies. Comparable as an emerging disease-modifying allergy therapy targeting similar pediatric and food allergy patient segments.
- Aimmune Therapeutics (Nestlé Health Science): Developer of FDA-approved oral immunotherapy for peanut allergy (Palforzia). Comparable to Allergychoices as a food allergy disease-modifying therapy addressing similar patient populations, though via an FDA-approved biologic rather than compounded SLIT.
Broad incumbents
- Greer Laboratories: Established U.S. allergen extract manufacturer and immunotherapy provider with a broad portfolio spanning SCIT and SLIT. Comparable as an incumbent supplying and supporting allergy immunotherapy practices.
- Antigen Laboratories: U.S. supplier of allergen extracts used in both SCIT and SLIT compounding. Comparable as an upstream input provider and broader immunotherapy incumbent whose extracts Allergychoices itself relies on for custom formulations.
Direct peers
- ALK-Abelló: Major allergy immunotherapy company producing both subcutaneous and sublingual treatments, including FDA-approved SLIT tablets (e.g., Odactra). Directly comparable as a SLIT competitor with overlapping prescriber channels and a multi-decade clinical heritage.
- United Allergy Services: Provides allergy testing and immunotherapy services (primarily SCIT) inside primary care and employer clinics. Comparable to Allergychoices' provider-channel and on-site clinic motions, with a similar focus on expanding immunotherapy beyond traditional allergist offices.
- HAL Allergy Group: Developer and manufacturer of allergen-specific immunotherapy products including sublingual formulations. Comparable to Allergychoices in the SLIT product category and prescriber support model.
- Leti Pharma: European biopharmaceutical company specializing in allergen-specific immunotherapy, including SLIT products. Comparable as a dedicated SLIT developer and formulator with similar prescriber education and dosing protocols.
- Stallergenes Greer: Global leader in allergy immunotherapy, offering both SCIT and SLIT products. Directly comparable to Allergychoices as a SLIT provider serving allergists and patients, though at significantly larger scale and with FDA/EMA-approved products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Allergychoices social profiles
Digital presenceAllergychoices compliance and trust
Trust signalCompliance1 record
Allergychoices financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allergychoices leadership team
Management profileNumber of profiles
Profiles1 record
Allergychoices funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allergychoices M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allergychoices
What does Allergychoices do?
Allergychoices is a healthcare services and pharmacy company that formulates and dispenses personalized sublingual immunotherapy (allergy drops) under the proprietary La Crosse Method Protocol. Its licensed pharmacy takes FDA-approved antigen extracts and produces custom 90-day prescriptions tailored to each patient's allergic fingerprint, while the company also trains and supports a network of 2,000+ allergists, ENTs, and Direct Primary Care providers, and delivers an Allergy Control Program turnkey offering for employer health plans.
Is Allergychoices a public or private company?
Allergychoices is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Allergychoices founded?
Allergychoices was founded in 2000. It employs 11 to 50 people.
Where is Allergychoices based?
Allergychoices is headquartered in Onalaska, United States, in the North America region.
How does Allergychoices make money?
Three revenue lines are on record. Prescription Allergy Drop Sales are the primary driver. The others are provider Training and Support Services and allergy Control Program (Employer).
Who are Allergychoices's main competitors?
Emerging players on record are Alladapt Immunotherapeutics, DBV Technologies and Aimmune Therapeutics (Nestlé Health Science). Broad incumbents are Greer Laboratories and Antigen Laboratories. Direct peers are ALK-Abelló, United Allergy Services, HAL Allergy Group, Leti Pharma and Stallergenes Greer.
Does Allergychoices have an API?
No public API is recorded for Allergychoices.
What industry is Allergychoices in?
Allergychoices's product category is Allergy Treatment Services. Its primary akta.pro industry code is HLAKAAAF, Allergen Immunotherapy (SCIT/SLIT) Services, with a secondary code of HLAKAAAA, Allergy & Immunology Clinics. Its NAICS code is 62111 and its SIC code is 8011.